Senti Biosciences (NASDAQ:SNTI) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Senti Biosciences (NASDAQ:SNTI) from a strong sell rating to a hold rating in a research report report published on Saturday.

Several other research firms have also recently commented on SNTI. Weiss Ratings reissued a “sell (e+)” rating on shares of Senti Biosciences in a research note on Thursday, January 22nd. Chardan Capital raised their price target on Senti Biosciences from $12.00 to $13.00 and gave the company a “buy” rating in a report on Tuesday, December 9th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Senti Biosciences currently has an average rating of “Moderate Buy” and a consensus price target of $8.50.

Senti Biosciences Price Performance

SNTI opened at $0.77 on Friday. The stock has a market capitalization of $20.29 million, a P/E ratio of -0.24 and a beta of 2.12. The company’s 50 day simple moving average is $0.94 and its 200-day simple moving average is $1.38. Senti Biosciences has a one year low of $0.77 and a one year high of $5.10.

Senti Biosciences (NASDAQ:SNTI) last posted its quarterly earnings data on Friday, March 27th. The company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.10). The company had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $1.00 million. As a group, analysts anticipate that Senti Biosciences will post -14.54 EPS for the current year.

Institutional Trading of Senti Biosciences

A number of institutional investors have recently bought and sold shares of SNTI. Jane Street Group LLC bought a new stake in shares of Senti Biosciences during the 4th quarter valued at $40,000. Virtu Financial LLC acquired a new position in shares of Senti Biosciences in the 4th quarter valued at $46,000. Citadel Advisors LLC bought a new position in shares of Senti Biosciences in the 3rd quarter worth $117,000. Geode Capital Management LLC boosted its position in shares of Senti Biosciences by 395.6% in the 2nd quarter. Geode Capital Management LLC now owns 147,314 shares of the company’s stock worth $311,000 after purchasing an additional 117,588 shares during the last quarter. Finally, Armistice Capital LLC acquired a new stake in shares of Senti Biosciences during the second quarter worth $1,883,000. Institutional investors and hedge funds own 25.70% of the company’s stock.

Senti Biosciences Company Profile

Senti Biosciences (NASDAQ:SNTI) is a clinical-stage synthetic biology company focused on engineering next-generation cell therapies. The company’s platform leverages modular genetic circuits to sense disease signals and precisely control cellular functions, with the goal of improving safety and efficacy in oncology and immune-mediated diseases.

Senti’s core technologies include its SENTINEL circuit platform and SNIP receptor system, which enable programmable sensing of molecular cues and context-dependent payload release.